CXCL5



CXCL5

A1AA1G2GG2P3PP3A4AA4A5AA5A6AA6V7VV7L8LL8R9RR9E10EE10L11LL11R12RR12C13CC13V14VV14C15CC15L16LL16Q17QQ17T18TT18T19TT19Q20QQ20G21GG21V22VV22H23HH23P24PP24K25KK25M26MM26I27II27S28SS28N29NN29L30LL30Q31QQ31V32VV32F33FF33A34AA34I35II35G36GG36P37PP37Q38QQ38C39CC39S40SS40K41KK41V42VV42E43EE43V44VV44V45VV45A46AA46S47SS47... and 31 more residue(s)...... and 31 more residue(s)

SMILES None
InChIKey None
Sequence AGPAAAVLRELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEICLDPEAPFLKKVIQKILDGGNKEN

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Ligand site mutations US28


No bioactivity data available.

CXCL5

A1AA1G2GG2P3PP3A4AA4A5AA5A6AA6V7VV7L8LL8R9RR9E10EE10L11LL11R12RR12C13CC13V14VV14C15CC15L16LL16Q17QQ17T18TT18T19TT19Q20QQ20G21GG21V22VV22H23HH23P24PP24K25KK25M26MM26I27II27S28SS28N29NN29L30LL30Q31QQ31V32VV32F33FF33A34AA34I35II35G36GG36P37PP37Q38QQ38C39CC39S40SS40K41KK41V42VV42E43EE43V44VV44V45VV45A46AA46S47SS47... and 31 more residue(s)...... and 31 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Ligand site mutations US28


Compound is not listed as a drug.